Praecis, GlaxoSmithKline deal

Under a previously announced tender offer to acquire PRCS for $5 a share, GSK paid $46.2 million for about 86% of PRCS's outstanding stock (see BioCentury, Jan. 1). GSK plans to buy the remaining shar...